| DB ID | MyCo_1577 |
| Title | False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam |
| Year | 2007 |
| PMID | 17604427 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Hematological Malignancy |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomamman |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | From September 2004 to May 2005, a cohort of 78 adult hematological cancer patients treated in the Hospital Doce de Octubre, Madrid, Spain and stratified according to the scheme of Prentice et al., were prospectively analyzed (as a routine screening twice weekly) establishing the GM index (GMI) by using the commercially available sandwich ELISA (Platelia Aspergillus) until the risk condition for developing IFI had subsided. All patients were nursed in rooms with HEPA filtration. The clinical assessment of our patients is the standardof care in tertiary hospitals, and has been described by ourgroup elsewhere. |
| Cohort No. | 78 |
| Age Group | None |
| P Value | p<0.01 |
| Sensitivity | 1 |
| Specificity | 0.88 |
| Positive Predictive Value | 0.47 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Sandwich ELISA Kit (Platelia Aspergillus, Bio-Rad, Marnes La Coquette, France) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
